| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
T3-ATA (S-isomer) targets the Thyroid Hormone Receptor (TR), primarily the TRalpha and TRbeta subtypes. As the active S-isomer, it mimics the physiological effects of endogenous triiodothyronine (T3) by binding to these nuclear receptors and modulating gene transcription involved in metabolism, growth, and development.
|
|---|---|
| ln Vitro |
In vitro studies show that T3-ATA (S-isomer) is the biologically active form of T3-ATA. It binds to thyroid hormone receptors with high affinity, as the S-isomer is the configuration that enables proper docking within the receptor‘s ligand-binding pocket, thereby initiating the transcriptional cascade typical of T3.
|
| ln Vivo |
In vivo data for this specific isomer is not available. As a thyroid hormone analog, it would be expected to regulate metabolism, heart rate, and body temperature in animal models, but its specific properties as a research tool require further characterization.
|
| Enzyme Assay |
Cell-free ligand-binding assays for thyroid hormone analogs use purified thyroid hormone receptors (TRalpha and TRbeta). The receptor is incubated with a radiolabeled T3 tracer and varying concentrations of the T3-ATA (S-isomer) competitor. After equilibrium, bound and free ligands are separated by filtration or charcoal adsorption, and the half-maximal inhibitory concentration (IC50) is calculated via scintillation counting.
|
| Cell Assay |
Cellular assays are performed in cells (e.g., HepG2 or pituitary GH3 cells) endogenously expressing thyroid hormone receptors. Cells are treated with the test compound for 24-48 hours. The activity is measured using a luciferase reporter gene construct containing a thyroid hormone response element (TRE) or by quantifying the mRNA expression of T3-responsive genes, such as malic enzyme (ME) and spot 14.
|
| Animal Protocol |
In vivo data is not available for this research compound. As a laboratory chemical for cell-based and in vitro studies, it is not typically formulated for animal pharmacokinetic or efficacy studies in a standard research setting.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties are not documented. As a laboratory chemical primarily for in vitro use, ADME (Absorption, Distribution, Metabolism, Excretion) data are not typically required or reported.
|
| Toxicity/Toxicokinetics |
Toxicological and safety profiles have not been formally established. This compound is intended for research use only and is not for human consumption. Standard safety precautions for handling fine chemicals should be followed.
|
| Additional Infomation |
T3-ATA (S-isomer) is the active S-enantiomer of the T3-ATA molecule, serving as a thyroid hormone receptor (TR) ligand. It is used as a pharmacological tool to understand the structural requirements for TR binding and to probe the differential roles of TRalpha vs. TRbeta in physiological processes. It is intended for research use only and is not approved for clinical or therapeutic applications.
|
| Molecular Formula |
C19H16I3NO6S
|
|---|---|
| Molecular Weight |
767.11
|
| Exact Mass |
766.783
|
| CAS # |
2438721-48-1
|
| PubChem CID |
138377585
|
| Appearance |
White to off-white solid powder
|
| Density |
2.179±0.06 g/cm3(Predicted)
|
| Boiling Point |
717.9±60.0 °C(Predicted)
|
| LogP |
4.7
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
30
|
| Complexity |
615
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(=O)SCC(=O)N[C@@H](CC1=CC(=C(C(=C1)I)OC2=CC(=C(C=C2)O)I)I)C(=O)O
|
| InChi Key |
RHDAROOLVWCQRO-HNNXBMFYSA-N
|
| InChi Code |
InChI=1S/C19H16I3NO6S/c1-9(24)30-8-17(26)23-15(19(27)28)6-10-4-13(21)18(14(22)5-10)29-11-2-3-16(25)12(20)7-11/h2-5,7,15,25H,6,8H2,1H3,(H,23,26)(H,27,28)/t15-/m0/s1
|
| Chemical Name |
(2S)-2-[(2-acetylsulfanylacetyl)amino]-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 50 mg/mL (65.18 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3036 mL | 6.5180 mL | 13.0359 mL | |
| 5 mM | 0.2607 mL | 1.3036 mL | 2.6072 mL | |
| 10 mM | 0.1304 mL | 0.6518 mL | 1.3036 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
